<DOC>
	<DOCNO>NCT00004997</DOCNO>
	<brief_summary>The 5 q minus syndrome condition occurs due miss segment chromosome 5 normal genetic make-up cell responsible form blood cell . The condition cause patient inability make blood normally . Many patient syndrome need transfusion red blood cell , platelet , and/or white blood cell . Low level platelet may cause patient bleed easily low level whit blood cell make patient susceptible infection . A small number patient 5 q minus syndrome develop leukemia , often untreatable chemotherapy . Researchers believe one gene miss 5 q minus syndrome gene responsible make folic acid active body . Folic acid vitamin require normal blood production . The purpose study test effectiveness drug call leucovorin treatment 5 q minus syndrome . Leucovorin active form vitamin folic acid require miss gene activate . Patients participate study may may improve leucovorin treatment . However , study improve researcher understand disease may lead potential therapy disease .</brief_summary>
	<brief_title>Leucovorin Treatment 5 q Minus Syndrome</brief_title>
	<detailed_description>The objective protocol determine whether leucovorin treatment normalize hematopoietic cell growth differentiation patient 5q- syndrome may lack gene dihydrofolate reductase enzyme .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>All patient 18 year old old RA , RARS RAEB 5q deletion sole cytogenetic abnormality require transfusion support blood define need least one unit pack red blood cell per month great equal 2 month and/or thrombocytopenia defined platelet count less 50,000 , and/or severe neutropenia ( absolute neutrophil count le 500 ) eligible , include patient treat chemotherapy experimental agent retinoids , phenylbutyrate , amifostine , Vitamin D , ATG hematopoietic growth factor . Patients must transform acute leukemia ( great 20 % blast marrow aspirate ) . Patients must treatment growth factor experimental drug within 4 week prior entry protocol . Patients must ECOG performance status great 2 . Patients must active uncontrolled infection . No patient bone marrow transplant indicate primary therapy . Must able give inform consent . Patients must HIV positive . Patients must pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>Hematopoietic</keyword>
	<keyword>DHFR Enzyme</keyword>
	<keyword>Anemia</keyword>
	<keyword>Folic Acid</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Myelodysplastic</keyword>
</DOC>